| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-247 | |
| Phytochemical name or plant extracts | Methyl protogracillin (NSC-698792) | |
| PMID | 11460001 | |
| Literature evidence | Based on an analysis of the COMPARE computer program with methyl protogracillin as a seed compound, no compounds in the NCI's anticancer drug screen database have similar cytotoxicity patterns (mean graph) to that of methyl protogracillin, indicating a potential novel mechanism of the anticancer action involved. | |
| IUPAC name | (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-[[(1S,2S,4S,6R,7S,8R,9S,12S,13R,16S)-6-methoxy-7,9,13-trimethyl-6-[(3R)-3-methyl-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutyl]-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-en-16-yl]oxy]-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol | |
| Phytochemicals’ class or type of plant extracts | Saponin | |
| Source of phytochemicals or plant Extracts | Dioscorea collettii | |
| Geographical availability | China South-Central, China Southeast, Laos, Myanmar, Taiwan, Thailand, Vietnam | |
| Plant parts | Rhizome | |
| Other cancers | Breast cancer, Prostate cancer, Kidney cancer, Brain cancer, Colon cancer, Skin cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | As a result, it was found that methyl protogracillin was cytotoxic against all the tested cell lines from leukemia and solid tumors in the NCI's human cancer panel. It showed particular selectivity against one colon cancer line (KM12), one central nervous system (CNS) cancer line (U251), two melanoma lines (MALME-3M and M14), two renal cancer lines (786-0 and UO-31) and one breast cancer line (MDA-MB-231) with GI50< or =2.0 microM. The selectivity between these seven most sensitive lines and the least sensitive line (CCRF-CEM) ranged from 26- to 56-fold. In the same cancer subpanel, selectivity more than 15-fold was observed between MDA-MB-231 and MCF-7, NCI-ADR-RES, BT-549 in breast cancer. | |
| Cell line/ mice model | MDA-MB-231 , MCF-7, NCI-ADR-RES, BT-549, MALME-3M, M14, KM12, SF-539, U251MDA-MB-435, | |
| Additional information | Based on an analysis of the COMPARE computer program with methyl protogracillin as a seed compound, no compounds in the NCI's anticancer drug screen database have similar cytotoxicity patterns (mean graph) to that of methyl protogracillin, indicating a potential novel mechanism of the anticancer action involved. | |
| PubChem ID | 44566783 | |
| Additional PMIDs | 12820229 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:317817-1 | |
| Safety | The preliminary toxicity studies showed that the maximum tolerant dose was 600 mg/kg for methyl protoneogracillin to mice. |